Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Kathryn Egerton

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

K. Egerton1, T.A. Mitchell1, P. Gravells1, R. Katse1, M. Fisher1, M. Muthana1, C.E. Eyers2, P.A. Eyers2, H.E. Bryant1

Author affiliations

  • 1 Oncology & Metabolism, University of Sheffield Medical School, S10 2RX - Sheffield/GB
  • 2 Institute Of Systems, Molecular And Integrative Biology, University of Liverpool, L69 7BE - Liverpool/GB

Resources

This content is available to ESMO members and event participants.

Abstract 18P

Background

Lung cancer accounts for 18% of cancer-related deaths globally, due to its high incidence and mortality rates. Radiotherapy is standard of care but radioresistance remains an area of clinical need. Aurora kinase B (AURKB) is a mitotic kinase with links to DNA damage repair (DDR). Given AURKB’s canonical functions in mitotic progression and its interactions with DDR proteins such as p53, Ku70 and H2AX, we hypothesized that inhibition of AURKB via the clinical inhibitor Barasertib (AZD1152) would radiosensitise NSCLC.

Methods

H460 cells were used as a NSCLC in vitro model. Survival fraction was assessed by clonogenic assay. Mitotic phenotypes and DDR markers were analysed by immunofluorescence. Phospho-Mass spectrometry (MS) was carried out on a Thermo Orbitrap LC-MS with TMT tagging and phospho-peptide enrichment using TiO2 beads. In vivo experiments were performed using a H460 xenograft model in Balb/c nude mice.

Results

We found that AURKB inhibition by Barasertib and siRNA radiosensitises NSCLC in vitro. We assessed changes in peptide phosphorylation using global phospho-MS. Comparing IR and IR-Barasertib conditions, significant changes in phospho-peptides representing proteins involved in cell cycle regulation, DDR and survival signalling were observed. Consistent with this we found significant changes in the mitotic response of cells to IR when co-treated with Barasertib. There were greater mitotic defects in Barasertib treated cells including centrosomal amplification and chromosomal segregation defects. Live cell microscopy indicated that Barasertib treatment leads to greater mitotic duration, increased occurrences of slippage, abscission regression and mitotic death compared with IR alone. Interestingly in contrast to indications of the phospho-MS data no change in the DNA repair dynamics of interphase cells was found. Trials are underway to test the efficacy of the IR-Barasertib combination on tumour growth in vivo.

Conclusions

In conclusion, Barasertib radiosensitises NSCLC cells by disrupting mitotic fate. This holds promise for clinical application in highly proliferative tumours.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

MRC DiMen DTP Weston Park Cancer Charity.

Disclosure

C.E. Eyers: Non-Financial Interests, Institutional, Advisory Board, Panel member: BBSRC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.